Skip to main content
Caplight Logo









Turn Biotechnologies

Turn Biotechnologies

Private
Mountain View, CaliforniaHealthcare & Life Scienceshttps://turn.bio

Last Round

M&A

May 21, 2026

Est. Valuation

$59M

Total Funding Raised

$30.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Turn Biotechnologies is a biotechnology company that develops mRNA-based therapies to repair and rejuvenate tissue at the cellular level by reprogramming the epigenome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

epigenetic reprogramminglipid nanoparticleLNPlongevity biotechmRNA therapeuticsrejuvenation therapyage-related diseasedrug delivery platformpreclinical researchbiotech licensingcellular reprogramminganti-agingrestorative medicinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Turn Biotechnologies Comparables

Compare Turn Biotechnologies with similar companies based on industry and business-model similarity.

Turn Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rejuvenation Technologies
80%
Oisín Biotechnologies
79%
Altos Labs
78%

Turn Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AMay 21, 2026
Series ASep 6, 2023
GrantJul 21, 2022
SeedApr 11, 2022
SeedApr 28, 2021

Key People

Founding team and executive leadership

Sergio Ruiz

Co-Founder Chief Operating Officer

Founding Team

Ric Peterson

Chief Financial Officer

Executive Team

Turn Biotechnologies Investors

Notable investors and investment history

Turn Biotechnologies investors
InvestorRounds
Khosla VenturesSeed, Series A
VitaDAOGrant
LongeVCSeed
ThreeD CapitalSeed
Vitality Healthspan FoundationSeed
Astellas Venture ManagementSeries A, Seed
Shanda GroupSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    Daewoong Pharmaceutical participated in the M&A round.

  • Sep 30, 2025

    Select assets acquired for $300M, anchored by pharma partnership.

Turn Biotechnologies Filings

Explore SEC and related filing metadata, where available.

Turn Biotechnologies filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Turn Biotechnologies's valuation, stock price, and market status.

Is turn.bio a public or private company?

turn.bio is a private company.

What is the current stock price of turn.bio?

turn.bio is a private company with no public stock price. No recent secondary market data is available.

How much is turn.bio worth (valuation)?

Valuation information for turn.bio is not publicly available.

Can I buy turn.bio stock?

turn.bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was turn.bio's last funding round?

turn.bio's most recent funding round was Series A on September 6, 2023.

Who are the main investors in turn.bio?

Key investors in turn.bio include Astellas Venture Management.

Will turn.bio IPO soon?

No public IPO plans have been announced for turn.bio.

How can I track turn.bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor turn.bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMountain View, California
Employee Range12
Year Founded2018
Last FundingMay 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?